Outcome of the Board Meeting held on 09.01.2026
IREDA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
IREDA's board approved audited standalone and consolidated financial results for Q3 FY26 and nine months ended December 31, 2025. Standalone Q3 revenue from operations rose about 26% year-on-year to ₹2,139.60 crore, while Q3 profit after tax jumped roughly 37% to ₹584.91 crore (₹425.38 crore in Q3 FY25). For nine months, revenue grew about 27% to ₹6,156.57 crore and PAT grew about 15% to ₹1,380.58 crore. Loan book stood at ₹87,884.76 crore with cumulative impairment allowance of ₹2,477.31 crore. Gross NPA ratio rose sharply to 3.97% as of December 2025 from 1.04% a year earlier, and CRAR was reported at 19.54%. Joint statutory auditors gave an unmodified opinion but flagged two emphasis of matter items.
Strong top-line and profit growth signals healthy business momentum, which is positive for shareholders. However, the sharp jump in Gross NPAs (1.04% to 3.97%), ₹400.24 crore of accounts kept as standard only due to High Court interim orders, and a restatement that lowered CRAR raise asset-quality concerns that could weigh on the stock in the short term despite the clean audit opinion.